Literature DB >> 19953533

Mutations of tropomyosin 3 (TPM3) are common and associated with type 1 myofiber hypotrophy in congenital fiber type disproportion.

Michael W Lawlor1, Elizabeth T Dechene, Emily Roumm, Amelia S Geggel, Behzad Moghadaszadeh, Alan H Beggs.   

Abstract

Congenital fiber type disproportion (CFTD) is a rare congenital myopathy characterized by hypotonia and generalized muscle weakness. Pathologic diagnosis of CFTD is based on the presence of type 1 fiber hypotrophy of at least 12% in the absence of other notable pathological findings. Mutations of the ACTA1 and SEPN1 genes have been identified in a small percentage of CFTD cases. The muscle tropomyosin 3 gene, TPM3, is mutated in rare cases of nemaline myopathy that typically exhibit type 1 fiber hypotrophy with nemaline rods, and recently mutations in the TPM3 gene were also found to cause CFTD. We screened the TPM3 gene in patients with a clinical diagnosis of CFTD, nemaline myopathy, and with undefined congenital myopathies. Mutations in TPM3 were identified in 6 out of 13 patients with CFTD, as well as in one case of nemaline myopathy. Review of muscle biopsies from patients with diagnoses of CFTD revealed that patients with a TPM3 mutation all displayed marked disproportion of fiber size, without type 1 fiber predominance. Several mutation-negative cases exhibited other abnormalities, such as central nuclei and central cores. These results support the utility of the CFTD diagnosis in directing the course of genetic testing. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19953533      PMCID: PMC2815199          DOI: 10.1002/humu.21157

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  19 in total

1.  Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion.

Authors:  J T den Dunnen; S E Antonarakis
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

2.  De novo missense mutation in a constitutively expressed exon of the slow alpha-tropomyosin gene TPM3 associated with an atypical, sporadic case of nemaline myopathy.

Authors:  H J Durling; P Reilich; J Müller-Höcker; B Mendel; D Pongratz; C Wallgren-Pettersson; P Gunning; H Lochmüller; N G Laing
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

3.  Assignment of a gene (NEMI) for autosomal dominant nemaline myopathy to chromosome I.

Authors:  N G Laing; B T Majda; P A Akkari; M G Layton; J C Mulley; H Phillips; E A Haan; S J White; A H Beggs; L M Kunkel
Journal:  Am J Hum Genet       Date:  1992-03       Impact factor: 11.025

Review 4.  The molecular basis for tropomyosin isoform diversity.

Authors:  J P Lees-Miller; D M Helfman
Journal:  Bioessays       Date:  1991-09       Impact factor: 4.345

5.  TPM3 mutation in one of the original cases of cap disease.

Authors:  Monica Ohlsson; Anna Fidzianska; Homa Tajsharghi; Anders Oldfors
Journal:  Neurology       Date:  2009-06-02       Impact factor: 9.910

6.  Familial congenital fiber type disproportion (CFTD) with an autosomal recessive inheritance.

Authors:  M Jaffe; J Shapira; Z Borochowitz
Journal:  Clin Genet       Date:  1988-01       Impact factor: 4.438

7.  Data on the distribution of fibre types in thirty-six human muscles. An autopsy study.

Authors:  M A Johnson; J Polgar; D Weightman; D Appleton
Journal:  J Neurol Sci       Date:  1973-01       Impact factor: 3.181

8.  Clinical course correlates poorly with muscle pathology in nemaline myopathy.

Authors:  M M Ryan; B Ilkovski; C D Strickland; C Schnell; D Sanoudou; C Midgett; R Houston; D Muirhead; X Dennett; L K Shield; U De Girolami; S T Iannaccone; N G Laing; K N North; A H Beggs
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

Review 9.  Congenital fiber type disproportion--30 years on.

Authors:  Nigel F Clarke; Kathryn N North
Journal:  J Neuropathol Exp Neurol       Date:  2003-10       Impact factor: 3.685

10.  Mutations of the slow muscle alpha-tropomyosin gene, TPM3, are a rare cause of nemaline myopathy.

Authors:  D Wattanasirichaigoon; K J Swoboda; F Takada; H-Q Tong; V Lip; S T Iannaccone; C Wallgren-Pettersson; N G Laing; A H Beggs
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

View more
  27 in total

1.  Clinical utility gene card for: nemaline myopathy.

Authors:  Kristen J Nowak; Mark R Davis; Carina Wallgren-Pettersson; Phillipa J Lamont; Nigel G Laing
Journal:  Eur J Hum Genet       Date:  2012-04-18       Impact factor: 4.246

2.  Treatment with ActRIIB-mFc Produces Myofiber Growth and Improves Lifespan in the Acta1 H40Y Murine Model of Nemaline Myopathy.

Authors:  Jennifer Tinklenberg; Hui Meng; Lin Yang; Fujun Liu; Raymond G Hoffmann; Mahua Dasgupta; Kenneth P Allen; Alan H Beggs; Edna C Hardeman; R Scott Pearsall; Robert H Fitts; Michael W Lawlor
Journal:  Am J Pathol       Date:  2016-04-18       Impact factor: 4.307

3.  Clinical utility gene card for: Nemaline myopathy - update 2015.

Authors:  Kristen J Nowak; Mark R Davis; Carina Wallgren-Pettersson; Phillipa J Lamont; Nigel G Laing
Journal:  Eur J Hum Genet       Date:  2015-02-25       Impact factor: 4.246

4.  Direct observation of tropomyosin binding to actin filaments.

Authors:  William M Schmidt; William Lehman; Jeffrey R Moore
Journal:  Cytoskeleton (Hoboken)       Date:  2015-06-30

5.  Non-fibro-adipogenic pericytes from human embryonic stem cells attenuate degeneration of the chronically injured mouse muscle.

Authors:  Gina M Mosich; Regina Husman; Paras Shah; Abhinav Sharma; Kevin Rezzadeh; Temidayo Aderibigbe; Vivian J Hu; Daniel J McClintick; Genbin Wu; Jonathan D Gatto; Haibin Xi; April D Pyle; Bruno Péault; Frank A Petrigliano; Ayelet Dar
Journal:  JCI Insight       Date:  2019-12-19

6.  Normal myofibrillar development followed by progressive sarcomeric disruption with actin accumulations in a mouse Cfl2 knockout demonstrates requirement of cofilin-2 for muscle maintenance.

Authors:  Pankaj B Agrawal; Mugdha Joshi; Talia Savic; Zoe Chen; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2012-02-17       Impact factor: 6.150

7.  Changes in cross-bridge cycling underlie muscle weakness in patients with tropomyosin 3-based myopathy.

Authors:  Coen A C Ottenheijm; Michael W Lawlor; Ger J M Stienen; Henk Granzier; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2011-02-28       Impact factor: 6.150

8.  Desensitizing mouse cardiac troponin C to calcium converts slow muscle towards a fast muscle phenotype.

Authors:  Svetlana Tikunova; Natalya Belevych; Kelly Doan; Peter J Reiser
Journal:  J Physiol       Date:  2018-08-02       Impact factor: 5.182

9.  Muscle weakness in TPM3-myopathy is due to reduced Ca2+-sensitivity and impaired acto-myosin cross-bridge cycling in slow fibres.

Authors:  Michaela Yuen; Sandra T Cooper; Steve B Marston; Kristen J Nowak; Elyshia McNamara; Nancy Mokbel; Biljana Ilkovski; Gianina Ravenscroft; John Rendu; Josine M de Winter; Lars Klinge; Alan H Beggs; Kathryn N North; Coen A C Ottenheijm; Nigel F Clarke
Journal:  Hum Mol Genet       Date:  2015-08-24       Impact factor: 6.150

10.  Mutation update and genotype-phenotype correlations of novel and previously described mutations in TPM2 and TPM3 causing congenital myopathies.

Authors:  Minttu Marttila; Vilma-Lotta Lehtokari; Steven Marston; Tuula A Nyman; Christine Barnerias; Alan H Beggs; Enrico Bertini; Ozge Ceyhan-Birsoy; Pascal Cintas; Marion Gerard; Brigitte Gilbert-Dussardier; Jacob S Hogue; Cheryl Longman; Bruno Eymard; Moshe Frydman; Peter B Kang; Lars Klinge; Hanna Kolski; Hans Lochmüller; Laurent Magy; Véronique Manel; Michèle Mayer; Eugenio Mercuri; Kathryn N North; Sylviane Peudenier-Robert; Helena Pihko; Frank J Probst; Ricardo Reisin; Willie Stewart; Ana Lia Taratuto; Marianne de Visser; Ekkehard Wilichowski; John Winer; Kristen Nowak; Nigel G Laing; Tom L Winder; Nicole Monnier; Nigel F Clarke; Katarina Pelin; Mikaela Grönholm; Carina Wallgren-Pettersson
Journal:  Hum Mutat       Date:  2014-05-01       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.